Spero Therapeutics develops tebipenem HBr, an oral antibiotic in development for complicated urinary tract infections in adults. It last closed at $0.74 on Nov 20, down 10.20% on the day. The next earnings report for SPRO is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, SPRO reported EPS of -$0.76 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 6.9% the session after earnings. Over the last 12 months SPRO insiders bought $0 of stock on the open market and sold $499K, according to SEC Form 4 filings.
AI Auto Pilots
Is SPRO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SPRO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on SPROStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
SPRO · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 36% below its 20 day and 49% below its 50 day average. It is 154% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.73, and the nearest resistance the Pivot at $0.76.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.8%/day
Key levels
$3.0852 week high+316.2%
$1.88200 day average+154.1%
$1.24100 day average+67.6%
$1.18Swing high (Oct 28)+59.5%
$1.1150 day average+50.0%
$1.0120 day average+36.5%
$0.79Pivot R1+6.8%
$0.76Pivot+2.7%
$0.74Last close
$0.7352 week low−1.4%
$0.71Pivot S1−4.1%
Indicators
RSI (14)
22.58
Oversold below 30
Oversold
MACD
-0.08
Below its signal line
Bearish
Stochastic
3.5
Near the bottom of its range
Oversold
ADX (14)
24.0
Weak trend
Williams %R
-96.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-234.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−28.0%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 28.6%/day
Key levels
$3.0852 week high+316.2%
$1.88200 day average+154.1%
$1.24100 day average+67.6%
$1.18Swing high (Oct 28)+59.5%
$1.1150 day average+50.0%
$1.0120 day average+36.5%
$0.79Pivot R1+6.8%
$0.76Pivot+2.7%
$0.74Last close
$0.7352 week low−1.4%
$0.71Pivot S1−4.1%
Indicators
RSI (14)
21.14
Oversold below 30
Oversold
MACD
-0.31
Below its signal line
Bearish
Stochastic
8.6
Near the bottom of its range
Oversold
ADX (14)
36.4
Trending down
Williams %R
-98.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-181.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.3%
Change over 10 sessions
Bearish
ATR (14)
$0.21
Typical daily range, 28.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SPRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow SPRO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for SPROHow many large options trades hit SPRO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in SPRO in the last 90 days.
From SEC Form 4 filings by SPRO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRO is in one of them and how their past SPRO trades turned out.
Spero Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments for rare diseases and diseases with high unmet need. Its main product candidate is tebipenem HBr, an oral tablet antibiotic in development to treat complicated urinary tract infections in adults with limited oral treatment options. The company has no products approved for sale, and GSK is developing and commercializing tebipenem HBr under a license agreement. Its intended users are adult patients and the physicians who treat them.